Literature DB >> 3309131

Effects of antihypertensive medications on vitality and well-being.

S Levine1, S H Croog, A Sudilovsky, M A Testa.   

Abstract

The effects of captopril, methyldopa, and propranolol were assessed for sense of well-being and vitality among 626 men with mild to moderate hypertension in a multicenter, randomized, double-blind clinical trial. After a 24-week treatment period, patients taking captopril, compared with patients taking methyldopa and propranolol, scored significantly higher on measures of well-being and vitality. In addition, patients on captopril had more favorable results in being able to keep up with their work and in not feeling tired or sleepy at work. The effects of each of the drugs manifested themselves at different periods. For example, the negative effects of methyldopa on vitality were evident by week 8, whereas the negative effects did not become manifest for propranolol until week 24. On the other hand, a steady progressive improvement in vitality scores was evident at week 8 and at week 24 for patients on captopril. The findings of the study also suggest that the effects of the treatment drugs were most marked in patients who had had previous antihypertensive medications and who were on single-drug therapy during the course of the clinical trial. Further, the differences between patients taking captopril and those on methyldopa and propranolol appear to be obscured by the addition of a diuretic. The findings of the study may guide the physician in orienting his or her patient and in planning and implementing a therapeutic regimen.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3309131

Source DB:  PubMed          Journal:  J Fam Pract        ISSN: 0094-3509            Impact factor:   0.493


  6 in total

1.  Energy, fatigue, or both? A bifactor modeling approach to the conceptualization and measurement of vitality.

Authors:  Nina Deng; Rick Guyer; John E Ware
Journal:  Qual Life Res       Date:  2014-11-02       Impact factor: 4.147

Review 2.  Health-related quality-of-life measurement in hypertension. A review of randomised controlled drug trials.

Authors:  I Côté; J P Grégoire; J Moisan
Journal:  Pharmacoeconomics       Date:  2000-11       Impact factor: 4.981

3.  Health-related quality of life assessment and the pharmaceutical industry.

Authors:  D A Revicki; M Rothman; B Luce
Journal:  Pharmacoeconomics       Date:  1992-06       Impact factor: 4.981

4.  Evaluating the psychometric characteristics of the Psychological General Well-Being Index with a new response scale.

Authors:  D A Revicki; N K Leidy; L Howland
Journal:  Qual Life Res       Date:  1996-08       Impact factor: 4.147

Review 5.  Neuropsychiatric consequences of cardiovascular medications.

Authors:  Jeff C Huffman; Theodore A Stern
Journal:  Dialogues Clin Neurosci       Date:  2007       Impact factor: 5.986

6.  Differences in Nutritional and Psychological Habits in Hypertension Patients.

Authors:  María Carreira-Míguez; Domingo Jesús Ramos-Campo; Vicente Javier Clemente-Suárez
Journal:  Biomed Res Int       Date:  2022-07-08       Impact factor: 3.246

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.